Medherant Overview
- Founded
-
2014
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.65M
- Investors
-
2
Medherant General Information
Description
Developer of a novel drug-in-adhesive transdermal delivery system designed to deliver higher doses of drugs through the skin. The company's drug delivery system consists of a novel adhesive into which the drug to be delivered is mixed and has a greater loading capacity than other drug-in-adhesive patch technologies, enabling patients to take medicines in higher concentrations with faster release rates and without the complications associated with oral drugs.
Contact Information
Website
www.medherant.co.uk
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Primary Office
- The Venture Centre
- University of Warwick Science Park, Sir William Lyons Road
- Coventry CV4 7EZ
- England, United Kingdom
+44 024 0000 0000
Medherant Timeline
Medherant Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 04-Apr-2023 | $3.65M | 000.00 | Completed | Clinical Trials - General | |
| 6. Later Stage VC | 12-May-2021 | 00.000 | 000.00 | 000.00 | Completed | Clinical Trials - General |
| 5. Grant | 01-Oct-2018 | 000.00 | 00.000 | Completed | Clinical Trials - General | |
| 4. Early Stage VC | 18-Jan-2018 | 00.000 | 00.000 | 000.00 | Completed | Clinical Trials - General |
| 3. Early Stage VC | 20-Oct-2016 | 00.000 | 00.000 | 00.000 | Completed | Startup |
| 2. Early Stage VC | 24-Mar-2016 | $570K | $1.02M | 00.000 | Completed | Startup |
| 1. Seed Round | 25-Mar-2015 | $448K | $448K | 00.000 | Completed | Startup |
Medherant Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Ordinary | 000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | ||
| B Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| B Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| B Ordinary | 7,444 | $0.013895 | $261.25 | $261.25 | 1x | $261.25 | 10.63% | |
| Ordinary | 84 | $0.013895 | $166.75 | $166.75 | 1x | $166.75 | 0.12% |
Medherant Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of a novel drug-in-adhesive transdermal delivery system designed to deliver higher doses of drugs through the
Drug Delivery
Coventry, United Kingdom
14
As of 2023
000.00
0000000000 0
000.00
000000
et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et d
0000 00000000
Miami, FL
00
As of 0000
000000000 -
000000
o consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000 00000000
Grand Rapids, MI
000
As of 0000
00000
000000000
00000
Add Comparison
Medherant Competitors (9)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Prosolus | Corporate Backed or Acquired | Miami, FL | 00 | 000000000 - | ||
| 000000 00000000000 | Private Equity-Backed | Grand Rapids, MI | 000 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly Angel backed | Orlando, FL | 0 | 00.000 | 00000000 | 00.000 |
| 000000 000000 | Formerly VC-backed | Fremont, CA | 00 | 00000 | 000000&0 | |
| 000 0000000 000000 | Private Equity-Backed | Andernach, Germany | 0000 | 000000000000 |
Medherant Patents
Medherant Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202112812-D0 | Patch | Inactive | 08-Sep-2021 | 0000000000 | |
| GB-202100993-D0 | Patch | Inactive | 25-Jan-2021 | ||
| GB-201905338-D0 | Patch | Inactive | 16-Apr-2019 | ||
| GB-201811833-D0 | Patch | Inactive | 19-Jul-2018 | 0000000000 | |
| GB-201811834-D0 | Patch | Inactive | 19-Jul-2018 | C09J175/08 |
Medherant Executive Team (6)
Medherant Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew McLean | Self | Board Member | 000 0000 |
| David Haddleton | Medherant | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Kenneth Cunningham MD | Self | Chairman | 000 0000 |
| Mark Payton Ph.D | Mercia Asset Management | Board Member | 000 0000 |
| William Burt Ph.D | Medherant | Chief Executive Officer & Board Member | 000 0000 |
Medherant Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Medherant Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Innovate UK | Government | Minority | 000 0000 | 000000 0 | |
| Mercia Asset Management | Growth/Expansion | Minority | 000 0000 | 000000 0 |